SG Americas Securities
DSGN icon

SG Americas Securities’s Design Therapeutics DSGN Stock Holding History

SG Americas Securities’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,980
Closed -$50K – 3104
2025
Q1 		$50K Sell
12,980
-687
-5% -$3.28K ﹤0.01% 3245
2024
Q4 		$84K Buy
13,667
+1,378
+11% +$7.98K ﹤0.01% 2786
2024
Q3 		$66K Buy
+12,289
New +$57.8K ﹤0.01% 3182
2024
Q2 		– Sell
-11,316
Closed -$46K – 2957
2024
Q1 		$46K Sell
11,316
-7,541
-40% -$20.1K ﹤0.01% 2778
2023
Q4 		$50K Sell
18,857
-1,050
-5% -$2.4K ﹤0.01% 2917
2023
Q3 		$47K Buy
+19,907
New +$92.8K ﹤0.01% 2951
2023
Q2 		– Sell
-15,040
Closed -$87K – 2497
2023
Q1 		$87K Buy
+15,040
New +$112K ﹤0.01% 2956
2022
Q4 		– Sell
-9,936
Closed -$166K – 3129
2022
Q3 		$166K Sell
9,936
-1,876
-16% -$37.3K ﹤0.01% 2466
2022
Q2 		$165K Buy
+11,812
New +$160K ﹤0.01% 2799
2022
Q1 		– Sell
-5,639
Closed -$121K – 3074
2021
Q4 		$121K Buy
+5,639
New +$96.8K ﹤0.01% 2958

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SG Americas Securities's DSGN Position: Q2 2025 in Review

SG Americas Securities sold out of Design Therapeutics (DSGN) in Q2 2025, closing a stake of 12,980 shares — an estimated $50K sold.

SG Americas Securities first reported a position in DSGN in Q4 2021 and held it in 10 quarters. The position peaked at $166K in Q3 2022. 92 funds tracked by Wall St. Rank hold DSGN as of Q2 2025.

  • SG Americas Securities reported no remaining Design Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 12,980 Design Therapeutics shares in Q2 2025, an estimated $50K.
  • SG Americas Securities first reported a position in Design Therapeutics in Q4 2021 and held it in 10 quarters.
  • SG Americas Securities's Design Therapeutics position peaked at $166K in Q3 2022.
  • 92 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.